BACK<<     
 
 
Advanced Cell Technology, Inc.
  SYMBOL: ( OTCBB: ACTC)
 
Paul Wotton, Ph.D   Edward Myles
President and CEO   CFO and Executive Vice President of Corporate Development
 
Interviewed On:
  Interview Formats:
  Other Options:
   
 
 
 
 
   INSTITUTIONAL OWNERSHIP / ANALYST COVERAGE
 

Maxim Group continues to cover Advanced Cell Technology with a Buy rating.

http://www.maximgrp.com/research/MaximUniverse.pdf

 
   DISCLAIMER
 

 

 
   OTHER INFORMATION
 

 http://ir.advancedcell.com/

 

 
   COMPANY PROFILE  
 

Advanced Cell Technology, Inc., ("ACT" or OTC: ACTC) is a biotechnology company that specializes in the development of cellular therapies for the treatment of diseases and conditions that impact tens of millions of people worldwide. The company applies stem cell-based technologies (both adult and human embryonic stem cells) and other proprietary methods in the field of regenerative medicine to bring patient-specific therapies from the lab bench to the bedside.

ACT's principal laboratory, GMP facility and corporate offices are in Marlborough, Massachusetts. ACT is led by an experienced management team and a world-class scientific team helmed, respectively, by Interim President, CFO and Executive Vice President of Corporate Development Edward Myles and Chief Scientific Officer Robert Lanza, M.D.

 

Therapeutic Platforms

ACT is using a combination of embryonic and adult stem cell technologies to develop novel therapies for indications with few or no alternatives. As documented in the journals Nature and Cell Stem Cell, ACT developed and holds in its repertoire the first-ever proven alternative method for successful hESC generation without harm to the embryo, called the "single-cell blastomere" technique, on which it holds broad intellectual property (IP) protection.

  • ACT has developed an embryonic stem cell-based therapy which provides a promising treatment option for a variety of incurable eye diseases. Age-related macular degeneration (AMD) alone afflicts more than 30 million people worldwide and is the leading cause of blindness in those older than 60 in the United States. Atrophic (dry) AMD accounts for the vast majority of all of those cases, and currently represents a market in Europe and the United States alone of $25-30 billion. Stargardt's disease, meanwhile, typically affects patients before they reach 20 years of age, and the pathology includes the death of photorecepters due to the loss of functional RPE cells, resulting in blindness.

    The company is focused on commercializing its human embryonic stem cell (hESC)-based Retinal Pigment Epithelial (RPE) therapy for degenerative retinal disease, for which it is currently conducting clinical trials. ACT is enrolling patients in two Phase 1/2 clinical trials to test the safety of the hESC-derived RPE cellular therapy for Stargardts Macular Dystrophy (SMD) and for Dry Age-Related Macular Degeneration (Dry AMD). Both the FDA and the European Medicines Agency (EMA) have also granted ACTs RPE cells Orphan status for treatment of Stargardts Disease.
  • ACTs hemangioblast (HG) program for the treatment of blood and cardiovascular diseases is currently in preclinical development. Hemangioblasts have multiple potential therapeutic applications for the repair of vascular tissue and could be a promising treatment option for a variety of diseases including cardiovascular diseases, diabetes and stroke. A paper published in Nature Methods documented ACTs successful generation of functional hemangioblast cells from human embryonic stem cells, and a paper published earlier this year in Cell Research indicated that hESCs could be a potentially unlimited source of platelets for transfusion.

 
 
   COMPANY PRESS RELEASE
 
 
09/05/14
-Advanced Cell Technology Announces Issuance of Patent Covering Dendritic Cells Manufacturing from Renewable Stem Cell Sources 
 
09/02/14
-Distinguished Scientists Join Advanced Cell Technology’s New Scientific Advisory Board 
 
08/27/14
-Advanced Cell Technology Announces 1:100 Reverse Stock Split 
 
07/03/14
-Advanced Cell Technology Secures $30 Million Equity Facility from Lincoln Park Capital 
 
07/01/14
-Advanced Cell Technology, Inc. Announces Paul K. Wotton Ph.D. Recognized as Ernst & Young (EY) 2014 Entrepreneur of the Year™  
 
06/24/14
-Advanced Cell Technology Appoints Paul K. Wotton, Ph.D, President and Chief Executive Officer 
 
06/06/14
-Advanced Cell Technology to Host Conference Call to Provide a Corporate Update; Announces Settlement of Litigation 
 
04/24/14
-Advanced Cell Technology’s Chief Scientific Officer Dr. Robert Lanza Named One of TIME Magazine’s 100 Most Influential People in t 
 
04/01/14
-Advanced Cell Technology to Host Conference Call to Provide a Corporate Update 
 
03/24/14
-New Mesenchymal Stem Cell Population from Human Pluripotent Stem Cells Displays Potent Immunomodulatory and Therapeutic Properties 
 
03/21/14
-Advanced Cell Technology to Present at Regenenerative Medicine Investor Day March 26, 2014 
 
01/22/14
-Advanced Cell Technology Announces Change in Management 
 
12/18/13
-Advanced Cell Technology Announces Release of New Edition of Definitive Resource in Tissue Engineering 
 
12/12/13
-Advanced Cell Technology Appoints Eddy Anglade M.D. Executive Vice President of Clinical Development 
 
11/12/13
-Advanced Cell Technology Announces 2013 Third Quarter Results 
 
10/21/13
-ACT’s Dr. Robert Lanza to Deliver Keynote Lecture at the World Conference on Regenerative Medicine 
 
10/18/13
-Advanced Cell Technology to Webcast 2013 Annual Shareholders’ Meeting on Tuesday, October 22nd 
 
09/25/13
-Advanced Cell Technology to Present at 2013 Aegis Capital Healthcare Conference 
 
09/24/13
-ACT’s Dr. Robert Lanza to Receive the Il Leone di San Marco Award in Medicine 
 
09/19/13
-ACT Files Investigational New Animal Drug (INAD) Application with FDA to Treat 10 Different Disease Indications Using Pluripotent  
 
08/12/13
-Advanced Cell Technology Files Preliminary Proxy Statement with Securities and Exchange Commission 
 
08/07/13
-Advanced Cell Technology Announces Second Quarter 2013 Results 
 
08/05/13
-Advanced Cell Technology to Host Conference Call to Discuss 2013 Second Quarter Results and Provide a Corporate Update on Wed 8/7 
 
07/17/13
-ACT Secures Approval from Data Safety Monitoring Board to Complete Third Patient Cohort in All Three Clinical Trials 
 
06/10/13
-ACT’s Dr. Robert Lanza to Deliver Keynote Address at Brigham & Women’s Hospital Regenerative Medicine Center Inaugural Symposium 
 
05/23/13
-ACT Appoints Edward Myles as Chief Financial Officer 
 
05/16/13
-ACT Confirms Clinical Trial Participant Showed Improvement in Vision from 20/400 to 20/40 Following Treatment 
 
05/09/13
-Advanced Cell Technology Announces 2013 First Quarter Results 
 
05/06/13
-Advanced Cell Technology to Host Conference Call to Discuss 2013 First Quarter Results and Provide a Corporate Update on Thursday 
 
04/23/13
-ACT Initiates Higher-Dosage Patient Treatment in European Clinical Trial for Macular Degeneration 
 
04/16/13
-Advanced Cell Technology to Present at Regen Med Investor Day 2013 
 
04/15/13
-ACT Treats First Patient with Better Vision in Clinical Trial for Stargardt’s Macular Dystrophy 
 
04/01/13
-ACT Initiates Treatment of Higher-Dosage Cohort in Clinical Trials for Dry Age-Related Macular Degeneration and Stargardt’s... 
 
03/22/13
-ACT’s Chief Scientific Officer Dr. Robert Lanza to Deliver the Nerem Lecture 2013 at the 17th Annual Hilton Head Workshop 
 
03/14/13
-Advanced Cell Technology Receives Approval from Data Safety Monitoring Board (DSMB) to Initiate Treatment of Third Patient Cohort  
 
03/12/13
-ACT’s Dr. Robert Lanza Voted Top 4 “Most Influential People on Stem Cells” 
 
03/07/13
-Advanced Cell Technology Announces Fourth-Quarter and Year-end Results 
 
03/04/13
-Advanced Cell Technology to Announce Fourth Quarter and Year-end Results on Thursday March 7th 
 
02/11/13
-ACT’s Clinical Partner Receives FDA Approval to Initiate Clinical Trial Using Company’s hESC-derived Cells to Treat Severe Myopia 
 
02/08/13
-Advanced Cell Technology to Present at 15th Annual BIO CEO & Investor Conference 
 
01/22/13
-Patients with Better Vision to be Enrolled in ACT’s Clinical Trials for Macular Degeneration 
 
01/17/13
-Advanced Cell Technology Announces Settlement of Litigation 
 
01/08/13
-Advanced Cell Technology Achieves Clinical Milestone 
 
01/07/13
-Advanced Cell Technology to Present at Biotech Showcase™ 2013 
 
12/20/12
-New Scientist Magazine Selects ACT’s Induced Pluripotent Stem (iPS) Cell-Derived Human Platelet Program As One of ‘10 Ideas That W 
 
12/19/12
-Advanced Cell Technology Elects Not to Complete Reverse Split 
 
12/17/12
-ACT Announces Completion of Higher-Dosage Cohort in European Clinical Trial for Stargardt’s Macular Dystrophy 
 
12/02/12
-Advanced Cell Technology to Participate on Panels and Host Experts Luncheon at 2012 World Stem Cell Summit 
 
11/28/12
-ACT Announces Completion of Higher-Dosage Cohort in Both U.S. Clinical Trials 
 
11/09/12
-Advanced Cell Technology Announces Interim Data from Its Three Ongoing Macular Degeneration Trials 
 
11/05/12
-Advanced Cell Technology to Announce Third Quarter Financial Results on Thursday, November 8th 
 
11/01/12
-ACT Announces Data and Safety Monitoring Board (DSMB) Approval to Complete Second Patient Cohort in Clinical Trial for Dry AMD 
 
10/26/12
-Advanced Cell Technology to Present at Stem Cell Meeting on the Mesa’s 2nd Annual Investor and Partnering Forum 
 
10/22/12
-ACT’s European Clinical Trial Advances to First Patient Treatment with Higher Dosage of Embryonic Stem Cell-Derived Retinal Pigmen 
 
10/18/12
-ACT Announces Second Stargardt’s Disease Patient Treated with Higher Dosage of Embryonic Stem Cell-Derived RPE Cells 
 
10/09/12
-ACT Announces Approval to Treat Additional Stargardt’s Disease Patients with Higher RPE Dosage in Both U.S. and European Trials 
 
09/28/12
-New Edition of Definitive (Two-Volume) Resource in Stem Cells Released Today 
 
09/20/12
-Advanced Cell Technology Secures New $35 Million Funding Commitment from Lincoln Park Capital 
 
09/18/12
-ACT to Present at Terrapinn’s Stem Cells & Regenerative Medicine Congress in Boston 
 
09/07/12
-Advanced Cell Technology to Present at 14th Annual Rodman & Renshaw Global Investment Conference 
 
09/04/12
-ACT’s Chief Scientific Officer Dr. Robert Lanza to Deliver Opening Keynote Address at 4th Annual Stem Cell Symposium in Singapore 
 
08/27/12
-ACT Comments on U.S. Appeals’ Court’s Dismissal Ruling in Case Challenging Federal Funding of Embryonic Stem Cell Research 
 
08/20/12
-ACT Announces Scotland’s NHS Lothian as Additional Site for EU Clinical Trial Using hESC-Derived RPE Cells for Macular Degeneratio 
 
08/08/12
-Advanced Cell Technology Announces 2012 Second Quarter Results 
 
08/02/12
-ACT Announces First Dry AMD Patient Treated with Higher Dosage of Embryonic Stem Cell-Derived RPE Cells 
 
07/31/12
-Advanced Cell Technology to Announce Second Quarter Financial Results on Wednesday, August 8th 
 
07/30/12
-ACT Treats 10th Patient in Embryonic Stem Cell Trials for Macular Degeneration 
 
07/26/12
-ACT Issued Broad Patent for Human RPE Cells Derived From All Types of Pluripotent Stem Cells 
 
07/12/12
-ACT Announces First Stargardt Patient Treated With Higher Dosage of Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells 
 
07/09/12
-ACT Secures Approval to Proceed with Increased RPE Dosage for Patients in Clinical Trial for Dry AMD 
 
07/02/12
-ACT Announces Second Patient with Stargardt’s Disease Treated in EU Clinical Trial  
 
06/15/12
-Advanced Cell Technology to Present at the 2012 Bio International Convention and the Clinical Outlooks for Regenerative Medicine M 
 
05/18/12
-Advanced Cell Technology to Present at World Stem Cells & Regenerative Medicine Congress in London 
 
05/07/12
-Advanced Cell Technology to Host Conference Call to Discuss 2012 First Quarter Results and Provide Corporate Update on Wed May 9th 
 
05/02/12
-ACT Announces Massachusetts Eye and Ear as Additional Site for Clinical Trial for Dry AMD Using Human Embryonic Stem Cell-Derived  
 
04/26/12
-Advanced Cell Technology Announces Webcast of Corporate Presentation at Annual Shareholders’ Meeting Today 
 
04/24/12
-ACT Announces Data and Safety Monitoring Board (DSMB) Approval to Increase RPE Dosage for Stargardt’s Disease Patients in U.S. Tri 
 
04/20/12
-ACT Announces Third Dry AMD Patient Treated in Clinical Trial 
 
04/16/12
-ACT Announces Second Patient with Dry AMD Treated in U.S. Clinical Trial with RPE Cells Derived from Embryonic Stem Cells 
 
04/13/12
-Advanced Cell Technology to Webcast 2012 Annual Shareholders’ Meeting on April 26th 
 
04/09/12
-ACT Appoints Michael Heffernan to Board of Directors 
 
04/04/12
-ACT Announces Approval of Bascom Palmer Eye Institute as Additional Site for Stem Cell Clinical Trial for dry AMD 
 
03/14/12
-ACT Announces Filing of Definitive Proxy 
 
03/13/12
-Advanced Cell Technology to Present at the 24th Annual ROTH Conference 
 
02/29/12
-Advanced Cell Technology To Announce 2011 Fourth Quarter and Year-End Results on March 1st 
 
02/15/12
-Advanced Cell Technology Announces Approval of Wills Eye Institute as Additional Site for Stem Cell Clinical Trial for Stargardt’s 
 
02/13/12
-ACT Announces Third Patient with Stargardt’s Disease Treated in U.S. Clinical Trial with RPE Cells Derived from Embryonic Stem Cel 
 
01/30/12
-ACT Announces Aberdeen Royal Infirmary in Scotland as Additional Site for Phase 1/2 Clinical Trial Using hESC-Derived RPE Cells fo 
 
01/25/12
-ACT Announces that Additional Patient with Stargardt’s Disease Has Undergone Embryonic Stem Cell Transplantation at UCLA’s Jules S 
 
01/23/12
-ACT Announces Europe’s First Human Embryonic Stem Cell Transplant in Patient with Stargardt’s Disease 
 
01/23/12
-ACT Publishes First Report of Embryonic Stem Cell (ESC)-Derived Cells Transplanted Into Patients 
 
01/23/12
-From NYTimes: Stem Cell Study May Show Advance 
 
01/17/12
-Leading Eye Institute to Participate in ACT’s Embryonic Stem Cell Clinical Trial for Macular Degeneration 
 
01/09/12
-Advanced Cell Technology To Present in the Regenerative Medicine Insight Track at the Biotech Showcase™ 2012 in San Francisco 
 
12/19/11
-Advanced Cell Technology Responds To Investor Inquiries 
 
12/12/11
-ACT Announces Settlements and Filing of Preliminary Proxy 
 
12/06/11
-ACT Announces Two New Appointments to Board of Directors 
 
11/30/11
-Advanced Cell Technology to Present at 2011 Stem Cell Meeting on the Mesa’s Investor and Partnering Forum 
 
11/09/11
-Advanced Cell Technology Announces 2011 Third Quarter Results 
 
11/07/11
-Advanced Cell Technology to Host Conference Call on Wednesday, Nov 9th to Discuss 2011 Third Quarter Results and Provide Update on 
 
10/19/11
-European Ruling May Not Impact Stem Cell Lines Derived Using Advanced Cell Technology's Single-Blastomere Method 
 
10/05/11
-Scientific Luminary Dr. Robert Langer Joins ACT’s Board of Directors 
 
10/03/11
-ACT Chairman and CEO Gary Rabin to Present at World Stem Cell Summit 
 
09/28/11
-ACT Receives Approval from Data and Safety Monitoring Board (DSMB) to Treat Next Patients in Stem Cell Clinical Trials 
 
09/27/11
-Due Diligence And Speculative Biotech Investing 
 
09/22/11
-ACT Receives Approval for First Human Embryonic Stem Cell Trial in Europe 
 
09/19/11
-ACT Secures First Patent for Generating Hemangioblast Cells to Treat a Broad Spectrum of Vascular and Hematopoietic Disorders 
 
09/08/11
-Advanced Cell Technology to Present at Two Upcoming Conferences 
 
08/08/11
-Advanced Cell Technology Announces 2011 Second Quarter Results 
 
08/02/11
-Advanced Cell Technology to Host Conference Call to Discuss 2011 Second Quarter Results and Provide Corporate Update on Monday 
 
07/27/11
-Advanced Cell Technology and Geron Aim to Shatter Stem Cell Myths 
 
07/21/11
-ACT Obtains Exclusive License for Hemangioblast Technology in North America 
 
07/14/11
-ACT Announces First Patients Undergo Embryonic Stem Cell Transplantation Treatment for Stargardt's Disease and Macular Degeneratio 
 
07/12/11
-Roslin Cells and Pfizer in pluripotent stem cell evaluation agreement 
 
06/27/11
-ACT Granted EU Orphan Medicinal Product Designation for hESC-Derived RPE Cells for Treatment of Stargardt's Disease 
 
06/27/11
-The Tiniest Transplant 
 
06/21/11
-ACT and Roslin Cells Announce Collaboration for Storage and Distribution of Embryonic Stem Cells Using ACT's Blastomere Technology 
 
06/13/11
-Stem Cell Stocks Remain Some of the Most Volatile in the Marke 
 
06/03/11
-Advanced Cell Technology To Webcast 2011 Annual Stockholder’s Meeting To be Held on Thursday, June 9th 
 
06/01/11
-Stronger Climate Forecasted in Pharmaceuticals -- Insight on Advanced Cell Technology, Inc. and Genmed Holding Corp. 
 
05/16/11
-ACT Announces Oregon Health & Science University as Clinical Trial Site for its Phase 1/2 Clinical Trial Using hESC-Derived RPE Ce 
 
05/09/11
-Advanced Cell Technology Announces 2011 First Quarter Results 
 
05/05/11
-ACT Interim Chairman and CEO Gary Rabin to Present at World Stem Cells & Regenerative Medicine Congress in London 
 
05/02/11
-Advanced Cell Technology Praises Federal Appeals Court Ruling Allowing for Continued Federal Funding of Embryonic Stem Cell Resear 
 
04/28/11
-ACT Announces UCLA Institutional Review Board (IRB) Approval of its Phase 1/2 Clinical Trials using hESC-Derived RPE Cells for the 
 
04/26/11
-ACT's Chief Scientific Officer Robert Lanza, M.D., to Deliver Speech at 3rd International Collaborative Symposium on Stem Cell Res 
 
04/20/11
-ACT Files European Clinical Trial Application for Phase 1/2 Study Using Embryonic Stem Cells to Treat Macular Degeneration 
 
03/23/11
-ACT to Be Issued Broad Patent for Human ES Cell-derived RPE Cells in China 
 
03/21/11
-Advanced Cell Technology Announces 2010 Results 
 
03/17/11
-Advanced Cell Technology to Host Conference Call to Discuss 2010 Year-end Financial Results and Provide Corporate Update on Monday 
 
03/14/11
-Speculative Biotech Firms Grind Through Regulatory Process 
 
03/14/11
-ACT Interim Chairman and CEO Gary Rabin to Present at BIO-Europe Spring 2011 Conference 
 
03/10/11
-ACT Receives Positive Opinion for Orphan Drug Designation from European Medicines Agency for hESC-Derived RPE Cells for Treatment  
 
02/23/11
-ACT Secures Patent to Generate Embryonic Stem Cells Without Embryo Destruction 
 
02/11/11
-Advanced Cell Technology To Present at the 13th Annual BIO CEO & Investor Conference 
 
01/12/11
-Advanced Cell Technology Interim Chairman and CEO Gary Rabin to Present at OneMedForum Finance Conference in San Francisco 
 
01/11/11
-Joint Venture SCRMI Reports in Prestigious Scientific Journal that Embryonic Stem Cells are a Potentially Unlimited Source 
 
01/05/11
-Small-Cap Research on Advanced Cell Technology Inc. and Bioheart Inc. - Biotech Companies Success Pinned to Clinical Trials 
 
01/04/11
-Advanced Cell Technology Inc. is Today's Focus Stock on MicroStockProfit.com 
 
01/03/11
-Advanced Cell Technology Receives FDA Clearance For Clinical Trials Using Embryonic Stem Cells to Treat Age-Related Macular Degene 
 
12/31/10
-Advanced Cell Technology Secures $25 Million Funding Commitment 
 
12/23/10
-Advanced Cell Technology's Chief Medical Officer Featured on National Radio Show About Biotech Breakthroughs 
 
12/23/10
-Advanced Cell Technology Files in Europe for Orphan Drug Designation For Its RPE Cells for Treatment of Stargardt’s Disease 
 
12/15/10
-Goldman Small Cap Research Issues News Analysis Report Covering Recent Material Events at Advanced Cell Technology 
 
12/14/10
-Closer Look: Advanced Cell Technology Among Stem Cell Sector Stocks That Have Recently Set Themselves Apart From the Pack 
 
12/09/10
-Advanced Cell Technology's CEO Says Markets Are Just Starting to Appreciate the Significance of Their Stem Cell Derived Treatments 
 
12/02/10
-Advanced Cell Technology Strengthens Balance Sheet 
 
11/30/10
-Advanced Cell Technology Files IND with FDA for First Clinical Trial Using Embryonic Stem Cells to Treat Dry AMD 
 
11/23/10
-BUYINS.NET Updates Advanced Cell Technology SqueezeTrigger Report 
 
11/22/10
-Advanced Cell Technology Receives FDA Clearance For the First Clinical Trial Using Embryonic Stem Cells to Treat Macular Degenerat 
 
11/02/10
-Advanced Cell Technology Receives Federal Grant for Nearly $1 Million 
 
10/12/10
-Advanced Cell Technology To Present Today at 18th Annual BioPartnering Europe Conference 
 
09/29/10
-Advanced Cell Technology Provides Update on Its Myoblast Program 
 
09/22/10
-Drs. Robert Lanza and Kwang-Soo Kim Win Prestigious NIH Director's Award 
 
09/14/10
-Advanced Cell Technology Obtains Broad Patent Covering Use of Stem Cell-Derived RPE Cells to Treat Eye Disorders 
 
09/10/10
-Advanced Cell Technology to Present at the 12th Annual Rodman & Renshaw Global Investment Conference 
 
08/17/10
-ACT Poised to Obtain and Control Key Patents to Generating iPS Cells 
 
07/28/10
-ACT Files Documentation With FDA for Clinical Trials Using ES Cells to Treat Eye Disease 
 
07/26/10
-BUYINS.NET Updates Advanced Cell Technology SqueezeTrigger Report 
 
06/16/10
-Advanced Cell Technology Awarded Broad Patent for Production of Retinal Pigment Epithelial Cells 
 
05/26/10
-Emerging Stock Report Initiates Independent Research Coverage on Advanced Cell Technology, Inc. 
 
05/25/10
-Advanced Cell Technology to Present at the 11th Annual B. Riley & Co. Investor Conference in Santa Monica, California 
 
05/11/10
-Advanced Cell Technology's CEO William M. Caldwell, IV to Present at Two European Healthcare Conferences 
 
05/10/10
-Advanced Cell Technology's Chief Scientific Officer Dr. Robert Lanza Honored By BioWorld Magazine As Leader Who Could Shape Biotec 
 
04/23/10
-Advanced Cell Technology's Studies to Support Phase I Multicenter Trial of Patients with Stargardt's Macular Dystrophy Demonstrate 
 
04/05/10
-Advanced Cell Technology's Dr. Robert Lanza to Give Plenary, Keynote Address at the Translational Regenerative Medicine Forum 
 
03/18/10
-Liberty Analytics Co. Initiates Independent Research Coverage on Advanced Cell Technology, Inc. 
 
03/18/10
-Liberty Analytics Co. Initiates Independent Research Coverage on Advanced Cell Technology, Inc. 
 
03/17/10
-Advanced Cell Technology Announces Year-End Results 
 
03/10/10
-Advanced Cell Technology's Chairman and CEO William M. Caldwell IV Interviewed on Bloomberg Radio's Hays Advantage Show 
 
03/10/10
-Resort and Residence TV, a Full Time Television Programming Network That Is a Wholly Owned Subsidiary of Next One Interactive Inc  
 
03/04/10
-Biotech Stock Alert for Advanced Cell Technology Inc. Issued by InvestorSoup 
 
03/02/10
-Advanced Cell Technology's RPE Cells Granted Orphan Drug Status from FDA for Treatment of Stargardt's Macular Dystrophy 
 
02/16/10
-Advanced Cell Technology's Research Featured in Scientific American, USA Today and Newsweek 
 
02/11/10
-Therapeutic Cells Derived From Reprogrammed (iPS) Stem Cells Display Early Aging 
 
02/10/10
-Advanced Cell and Colleagues Report Therapeutic Cells Derived From iPS Cells Display Early Aging 
 
01/29/10
-Advanced Cell Technology's Chairman and CEO, William M. Caldwell IV, To Deliver Today Luncheon Keynote Address at 7th Insurance Li 
 
11/19/09
-Advanced Cell Technology Files IND With FDA For First Human Clinical Trial Using Embryonic Stem Cells to Treat Eye Disease 
 
09/23/09
-Emerging Stock Report Initiates Independent Research Coverage On Advanced Cell Technology, Inc 
 
09/22/09
-Advanced Cell Completing Pre-Clinical Activities in Preparation for IND Filing 
 
09/21/09
-Dr. Robert Lanza Featured on Michio Kaku's 'Explorations in Science' 
 
08/31/09
-Advanced Cell Technology To Address Shareholder Questions on Tuesday, September 8th 
 
08/13/09
-Dr. Robert Lanza is Featured Guest on Deepak Chopra's SIRIUS XM Stars Radio Show 
 
08/10/09
-Edmund Mickunas Named Vice President of Regulatory for Advanced Cell Technologies 
 
07/16/09
-Skymark Research Initiates Complimentary Research Coverage On Advanced Cell Technology, Inc. 
 
05/13/09
-Advanced Cell Technology Provides Single Blastomere Technology To CHA Bio & Diostech Co., Ltd. 
 
05/11/09
-Advanced Cell Technology Files Form 10-Q for its 2008 Second and Third Quarters 
 
04/14/09
-Advanced Cell Technology Moves towards Relisting on Over-the-Counter Bulletin Board 
 
03/30/09
-Advanced Cell Technology and CHA Bio & Diostech to Collaborate on RPE Technology Development in Korea 
 
03/12/09
-Advanced Cell Technology Prepares IND Filing With the Capability to Produce Stem Cell Lines without the Destruction of the Embryo 
 
03/11/09
-Advanced Cell Technology Secures $5 Million Credit Facility to Develop RPE Program for the Treatment of Diseases of the Eye 
 
03/04/09
-Advanced Cell Technology Receives Additional $400,000 in Funding 
 
02/02/09
-Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs 
 
01/23/09
-Advanced Cell Provides Corporate Update Company Anticipates Funding to File IND for Retinal Pigment Epithelium (RPE) Cells Program 
 
01/23/09
-Advanced Cell Provides Corporate Update 
 
01/05/09
-Functional Vasculature Generated From Advanced Cell Technologys Human Embryonic Stem Cells 
 
12/30/08
-Joint Venture Between CHA Biotech and Advanced Cell Technology to be called Stem Cell & Regenerative Medicine International 
 
12/18/08
-Advanced Cell Technology Licenses Non-Core Technology for $2.5 Million 
 
12/04/08
-Advanced Cell Technologys Study Published in Leading Hematology Journal 
 
12/01/08
-Leading Korean Biotech Company & Advanced Cell Technology Form JV 
 
11/17/08
-Advanced Cell Technology Comments on Technology Platform 
 
10/30/08
-Advanced Cell Technology, Inc. Increases Funding Commitment to $1 Million 
 
10/17/08
-Advanced Cell Receives $250,000 Tranche of Funding Commitment 
 
10/15/08
-Advanced Cell Technology's Dr. Robert Lanza Conference Co-Chair of International Forum on Stem Cells October 16-18, 2008, Tianjin, 
 
10/07/08
-Advanced Cell Technology, Inc. Receives $500,000 Funding Commitment 
 
09/09/08
-Advanced Cell Technology Announces Cost Reduction Program 
 
08/19/08
-Stem cells could allow "blood farms," company says 
 
08/11/08
-Advanced Cell Technology Licenses ACTCellerate Technology to BioTime, Inc. 
 
06/03/08
-Form 8-K for ADVANCED CELL TECHNOLOGY, INC.  
 
06/03/08
- Form 8-K for Advanced Cell Technology, Inc. 
 
04/10/08
-Advanced Cell Technology's Executive Invited to Present Today to FDA Advisory Committee on Cellular Tissue Therapies 
 
04/02/08
-Barbara Walters' ABC Network Television Special Highlights Role that Advanced Cell Technology's Embryonic Stem Cells Play in Preve 
 
03/12/08
-Advanced Cell Technology and Catholic Healthcare West Sign Clinical Agreement 
 
03/05/08
-Advanced Cell Technology Announces Catheter Supply Agreement with Biologics Delivery Systems Group 
 
02/29/08
-Advanced Cell Technology, Inc. Enters into License Agreement with Pharming Group N.V. 
 
02/21/08
-Advanced Cell Technology Demonstrates Efficient Generation of Functional Hepatocytes (Liver Cells) From Human Embryonic Stem Cells 
 
02/11/08
-Advanced Cell Technology Announces Presentation of Results from Myoblast Study at ISCTR World Symposium 
 
02/01/08
-Advanced Cell Technology Announces Completion of Pre-IND Meeting with the FDA for RPE Therapy for the Treatment of Retinal Degener 
 
01/10/08
-Advanced Cell Technology Announces Creation of Human Embryonic Stem Cell Lines Without the Destruction of Embryos 
 
01/08/08
-Advanced Cell Technology Awarded Grant from the NIH 
 
12/19/07
-Advanced Cell Technology Issues Letter to Investors 
 
12/06/07
-Advanced Cell Technology Seeking International Partners for Its Therapeutic Programs 
 
11/20/07
-Advanced Cell Technology's Chief Executive Officer Scheduled to Be Interviewed By Bloomberg Television Tonight 
 
11/07/07
-CHW Researcher Presents Results of ACT-Sponsored Trial Demonstrating Efficacy of ACT Myoblast Therapy for Heart Failure at AHA Mee 
 
11/07/07
-Advanced Cell Technology Announces 12-Month Results of Myoblast Therapy Trial 
 
11/06/07
-Advanced Cell Technology's Chief Scientific Officer Featured Speaker at American College of Rheumatology / Association of Rheumato 
 
11/05/07
-Advanced Cell Technology and the Casey Eye Institute at Oregon Health & Science University Present Results of Functional Studies f 
 
11/02/07
-Advanced Cell Technology Announces Executive Promotions 
 
11/01/07
-Advanced Cell Technology to Present at The Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5 
 
10/31/07
-Advanced Cell Technology's Chief Scientific Officer Delivers Keynote Address at Leading International Stem Cell Conference 
 
10/25/07
-Advanced Cell Presents Phase I(b) Data Demonstrating Safety and Optimal Dosage for Myoblast Program at TCT Conference and Expositi 
 
10/18/07
-Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conferen 
 
10/16/07
-ACT's Myoblast Trial Selected as Late Breaking Trial for AHA Conference 
 
10/11/07
-Advanced Cell Technology Announces the Promotion of Dr. Robert Lanza to Chief Scientific Officer 
 
09/24/07
-Advanced Cell Technology Completes Acquisition of Mytogen, Inc. 
 
09/20/07
-NIH Announces Advanced Cell Technology's 'Single Cell Embryo Biopsy Technique' as a Means to Derive Embryonic Stem Cells to be Con 
 
09/11/07
-Dr. Robert Lanza, VP of Research & Scientific Development, to Speak at the First Albany Capital Regenerative Technologies Conferen 
 
09/04/07
-Advanced Cell Technology Completes $10 Million Private Placement 
 
08/21/07
-Advanced Cell Technology's Dr. Robert Lanza Makes List of '100 Most Inspiring People in the Life-Sciences Industry' 
 
08/20/07
-Advanced Cell Technology Announces Proposed Financing 
 
08/16/07
-New Edition of Definitive Resource in Tissue Engineering Released Today 
   KEY PRODUCTS / SERVICES  
 

ACT owns or licenses more than 150 patents and patent applications related to stem cell therapy and regenerative medicine. ACT recently secured a patent on its embryo-safe single-blastomere technology and in June of 2010 secured a broad patent for production of RPE cells.

 
 
   
   
 
Copyright © 2001-2017. All Rights Reserved. Disclaimer | Privacy Policy